- Open Access
The impact of close surveillance on pregnancy outcome among women with a prior history of antepartum complications attributed to thrombosis: a cohort study
© Salim et al; licensee BioMed Central Ltd. 2008
Received: 06 September 2008
Accepted: 21 November 2008
Published: 21 November 2008
There is limited evidence, so far, as to the optimal management of women with a prior obstetric history of antepartum complications attributed to thrombosis. We aimed to investigate the contribution of close antepartum surveillance on pregnancy outcome among women with prior antepartum complications attributed to thrombosis.
The study was conducted on all women who were delivered, conceived and delivered again between January 2000 and January 2006 at a university teaching hospital. Women included were managed in previous pregnancy at a low risk setting and had unpredicted antepartum complications occurring at a gestational age of 23 weeks or more. Antepartum complications considered were intrauterine fetal death, neonates who were small for gestational age, severe pre-eclampsia and placental abruption. All women were tested for the presence of thrombophilia after delivery. In the following pregnancy, only women found to have any thrombophilia (thrombophilic group) were treated with enoxaparin. Both the thrombophilic group and the non-thrombophilic group (tested negatively for thrombophilia) were managed and observed closely at our high-risk pregnancy clinic.
Ninety-seven women, who conceived at least once after the diagnosis of the relevant antepartum complications, were included in this study. Forty-nine had any thrombophilia and 48 tested negatively. Composite antepartum complications (all antepartum complications considered) were reduced significantly after close antepartum surveillance in both groups. Mean birth weight and mean gestational age improved significantly and were comparable between the groups.
Close antepartum surveillance may contribute to improvement in the perinatal outcomes of women with prior antepartum complications attributed to thrombosis.
Severe pre-eclampsia, intrauterine growth restriction, intrauterine fetal death, and placental abruption affect 8% of pregnant women and collectively contribute to the largest proportion of maternal and fetal mortality and morbidity . Evidence has accumulated to suggest that these antepartum complications could have a common thrombogenic basis that manifested in the placenta as placental infarction, perivillous fibrin deposition, intervillous thrombosis and placental floor infarction [2, 3]. Although acquired and inherited thrombophilia had been reported to increase significantly the incidence of antepartum complications attributed to thrombosis [4–8], Mousa et al reported that no different or specific histological pattern could be identified among women with antepartum complications when thrombophilia positive and thrombophilia negative groups were compared .
There is limited evidence, so far, as to the optimal management of women with a prior obstetric history of antepartum complications attributed to thrombosis. Since these women are considered at a high risk of an adverse maternal or fetal outcome in subsequent pregnancies , we aim in this study to investigate the possible beneficial effect of close antepartum surveillance among these women who conceived and delivered again at our institution.
Women who had a previous pregnancy with antepartum complications occurring at a gestational age of 23 weeks or more were followed and tested for thrombophilia. Antepartum complications considered were unexplained intrauterine fetal death, neonates who were small for gestational age (SGA), severe pre-eclampsia and placental abruption. SGA was defined as birth weight below the 10th percentile. Severe pre-eclampsia was defined as blood pressure measuring above 140/90 combined with proteinuria (300 mg/24 h) and accompanied with one or more of the following complications: worsening blood pressure to a level above 160/110, HELLP syndrome (hemolysis, low platelet count and elevated liver enzymes), persistent severe headache or visual disturbances, persistent severe epigastric pain, nausea and vomiting, eclampsia, pulmonary edema, oligouria (urine output less than 500 cc/24 h), proteinuria of 5 g or more per 24 h and fetal growth restriction (below the 5th percentile). The study was conducted at a university teaching hospital on all women who were delivered, tested for thrombophilia after delivery, conceived and delivered again between January 2000 and January 2006. Women were tested for the mutation of guanine to adenine at nucleotide 1691 in the factor V gene (factor V Leiden), the mutation of cytosine to thymine at nucleotide 677 in the gene encoding methylenetetrahydrofolate reductase, and the mutation of guanine to adenine at nucleotide 20210 in the prothrombin gene. Women were also tested for protein C, protein S and antithrombin III deficiency; and the presence of antiphospholipid antibodies (lupus anticoagulant or anticardiolipin antibodies) and the results were confirmed in a second assay. Blood tests were done six weeks or more after the previous delivery. Women who had a previous pregnancy with antepartum complications that could be attributed to multiple gestations, having fetuses with major congenital anomalies or chromosomal abnormalities, fetal infection, chorioamnionitis, hydrops fetalis and diabetes mellitus were excluded. Only women found to have any thrombophilia (thrombophilic group) were treated for the first time, in the following pregnancy, with the low molecular weight heparin (LMWH), enoxaparin (Lovenox, Aventis, France). Enoxaparin was started after detection of fetal heart activity in the 1st trimester throughout gestation, and six weeks into the post-partum period. The enoxaparin dose was 40 mg once daily in women with a solitary thrombophilia and 80 mg daily (40 mg every 12 h) in women with combined thrombophilia. This higher dose was used based upon the significantly higher risk for pregnancy loss and stillbirth in women with combined thrombophilia . Aspirin at a dose of 100 mg (Aspe'gic nourrissons, Sanofi-Synthe'labo, France) daily was given in addition to enoxaparin to women with antiphospholipid antibodies. Additionally, all women received 5 mg folic acid daily. Both the thrombophilic group and the non-thrombophilic group were managed and observed closely at our high-risk pregnancy clinic during the study period. Surveillance of both groups included weekly blood pressure measurements and sonographic estimates of fetal weight at 4 weeks intervals. When fetal growth restriction (below the 10th percentile) was detected, sonographic fetal weight estimates were done every two weeks. In addition, non-stress testing (NST) twice weekly, umbilical artery Doppler and biophysical profile once weekly were also performed. Women detected to have fetal growth restriction with a reassuring fetal status were allowed to continue surveillance until term (37 weeks). At 37 – 38 weeks, induction of labor was considered. Women with a previous intrauterine fetal death had a weekly NST starting a week before the gestational age when fetal death was detected in the prior pregnancy. These women were induced between 38 – 39 weeks. Women who developed pre-eclampsia or placental abruption were managed according to the severity of the disease, fetal status and gestational age. Women were asked about bleeding episodes, signs of thrombosis, and symptoms of bone pain. Levels of platelets were followed monthly.
We compared perinatal outcomes within and between the groups before and after close surveillance. Perinatal outcomes included the reappearance of one or more of the thrombophilic complications considered (fetal death, SGA, severe pre-eclampsia and placental abruption), neonatal birth weight and Apgar score. Other parameters collected were maternal age and ethnicity. The local Institutional Review Board approved the study.
Data analysis was performed using the SPSS 14 statistical package (SPSS, Chicago, IL). Comparison of binary variables between thrombophilic and non-thrombophilic groups, were analyzed by Chi-square test or Fisher's exact test as appropriate. T test or Mann Withney test were used to compare continuous variables between the two independent groups. To assess the influence of treatment on the variables in each group, McNemar, Paired T test or Wilcoxon signed ranks test were applied as appropriate. Proportion of live born neonates per woman was calculated as number of live born neonates divided by number of births per woman. The same calculation was made regarding the proportion of preterm deliveries and complicated pregnancies per woman. A p value < 0.05 was considered significant.
The thrombophilic profile of the 49 women who belonged to the thrombophilic group.
Factor V Homozygote
Factor V Heterozygote + MTHFR homozygote
Factor V Heterozygote
Factor V Heterozygote + Protein S deficiency
Factor II Homozygote
Factor V Homozygote + Protein S deficiency
Factor II Heterozygote
ANT III deficiency + MTHFR homozygote
Protein S deficiency + Protein C deficiency
Protein C deficiency
Protein S deficiency
ANT III deficiency
Comparison of perinatal outcomes within the thrombophilic and non-thrombophilic groups before and after close surveillance.
(N = 49)
(N = 48)
Number of women
with at least one
surveillance N (%)
surveillance N (%)
surveillance N (%)
surveillance N (%)
Live born neonate
Comparison of the proportion of complications per woman within the thrombophilic and non-thrombophilic groups before and after close surveillance.
(N = 49)
(N = 48)
per woman, of
Live born neonate
63 (43) 
96 (20) 
74 (38) 
96 (21) 
30 (42) 
9 (29) 
42 (44) 
32 (46) 
70 (32) 
11 (31) 
63 (35) 
35 (46) 
Comparison between perinatal outcomes of thrombophilic and non-thrombophilic groups before and after close surveillance
Before close surveillance
After close surveillance
Thrombophilic group (N = 49)
Non-thrombophilic group (N = 48)
Thrombophilic group (N = 49)
Non-thrombophilic group (N = 48)
Proportion, per woman, of
Live born neonate*
63 (43) 
74 (38) 
96 (20) 
96 (21) 
30 (42) 
42 (44) 
9 (29) 
32 (46) 
Number of women who delivered at least one
Severe pre-eclampsia (%)
Placental abruption (%)
We did not observe any case of heparin-induced thrombocytopenia among the 49 women treated with LMWH. Likewise, there were no clinical manifestations of bone pain or bleeding complications related to LMWH treatment among the women.
The present report demonstrates that close antepartum surveillance at specialized clinics may contribute to improvement in the perinatal outcomes of women with prior antepartum complications attributed to thrombosis regardless of the presence of thrombophilia detected by our testing methods. Among these women, the incidence of any thrombophilic defect was 51%, which is, similar to that reported in the literature . The FVL mutation was the most common type of thrombophilia, accounting for 49% of all the thrombophilic defects. The incidence of thrombophilia was significantly higher among Arabs compared to Jews. The high incidence of thrombophilia among Israel's Arabs compared to Jews maybe explained by the high rate of consanguinity reported in that population [11, 12].
The present report demonstrates that among women with antepartum complications who were found to have inherited or acquired thrombophilia, close surveillance combined with antithrombotic therapy in subsequent gestations, resulted in a significant improvement in perinatal outcome, compared to the previous gestations. Contradictory reports are present in the literature regarding the effect and role of LMWH treatment on thrombophilic women with a history of pre-eclampsia, intrauterine growth restriction, placental abruption and fetal loss [13–19]. However, in view of the potential severe consequences of thrombophilia in pregnancy, several reports have recommended the use of anticoagulant therapy in the following pregnancies [20, 21]. A main issue which raised in this report is that these pregnancies, once diagnosed, are usually managed under close surveillance and, still, none of these studies had isolated the role of close antepartum surveillance on pregnancy outcome among these women. Thus it is still to be determined whether LMWH alone, close surveillance or both is responsible for the better outcome.
In this study, 49% of the women who had antepartum complications were tested negatively for thrombophilia and therefore were not treated with LMWH. After close surveillance alone in subsequent gestations, a significant improvement was observed in composite fetal outcome compared to previous gestations. Nevertheless, and probably expected, the number of women who had severe pre-eclampsia or delivered SGA neonates did not differ significantly with close surveillance alone. Close surveillance alone, decreased significantly the incidence of IUFDs per woman. Moreover, gestational age and birth weight were both improved, probably due to the opportunity of prolonging the gestational age under close surveillance. When comparing perinatal outcome between the groups, antepartum complications were reduced significantly in both groups after close surveillance. Moreover, gestational age at delivery, birth weight and the incidence of live born neonate per woman were comparable between the groups.
Comparing the thrombophilic and the non-thrombophilic group, who tested negatively for the thrombophilic defects studied, might seem ill advised. Nevertheless, both groups share probably the same uteroplacental histopathology. Mousa et al reported that no specific histological pattern could be identified among women with antepartum complications when thrombophilia positive and thrombophilia negative groups were compared and concluded that a poor correlation exists between thrombophilia status and pathological changes of the placenta in women with antepartum complications . Moreover, it cannot be ruled out that the non-thrombophilic group possesses thrombophilic defects that are unknown or were not studied in this report . We did not stratify the obtained results with the level of fasting total homocysteine, because all women were taking folic acid from at least 1 month before conception .
Moreover, we did not examine the maternal plasma levels of coagulation factor VIII, which had been reported to be associated with an increased risk for recurrent early pregnancy loss , or for protein Z deficiency and positive antiprotein Z antibodies, which had been described to increase the severity of the prothrombotic phenotype of FVL . Whether the non-thrombophilic group has an unrecognized thrombophilia or not, close surveillance without any other treatment improved their perinatal outcomes.
Although, and due to ethical issues, the women in both groups were not randomized and all got the same close antepartum surveillance, this study reveals that close surveillance at a specialized clinic may improve the perinatal outcomes of both thrombophilic and non-thrombophilic women with prior antepartum complications attributed to thrombosis. However, this study dose not separate the effect of LMWH and close antepartum surveillance on pregnancy outcome among the thrombophilic group and it still needs to be determined whether the additional treatment of LMWH is better than close surveillance alone. While this study cannot answer the latter issue, its results may be considered an intermediate step in allowing placebo to be compared to LMWH during pregnancy in thrombophilic women with previous placental dysfunction.
We thank Idit Lavi, Department of Community Health and Epidemiology (IL), Carmel Medical Center, Haifa, Israel, regarding the statistical support and we appreciate her advice and contribution for the study. Idit Lavi received no compensation.
- Hossain N, Paidas MJ: Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin Perinatol. 2007, 31: 208-212. 10.1053/j.semperi.2007.05.002.View ArticlePubMedGoogle Scholar
- Younis JS, Samueloff A: Gestational vascular complications. Best Pract Res Clin Haematol. 2003, 16: 135-151. 10.1016/S1521-6926(02)00099-3.View ArticlePubMedGoogle Scholar
- Mousa HA, Alfirevic1 Z: Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?. Hum Reprod. 2000, 15: 1830-1833. 10.1093/humrep/15.8.1830.View ArticlePubMedGoogle Scholar
- Weiner Z, Beck-Fruchter R, Weiss A, Hujirat Y, Shalev E, Shalev SA: Thrombophilia and stillbirth: possible connection by intrauterine growth restriction. BJOG. 2004, 111: 780-783. 10.1111/j.1471-0528.2004.00182.x.View ArticlePubMedGoogle Scholar
- Preston FE, Rosendaal FR, Walker ID: Increased fetal loss in women with heritable thrombophilia. Lancet. 1996, 348: 913-916. 10.1016/S0140-6736(96)04125-6.View ArticlePubMedGoogle Scholar
- Many A, Kupferminc MJ: Thrombophilia and adverse pregnancy outcome. Hematologica. 2003, 88: 729-731.Google Scholar
- Kupferminc MJ, Eldor A: Inherited thrombophilia and gestational vascular complications. Semin Thromb Hemost. 2003, 29: 185-194. 10.1055/s-2003-38834.View ArticlePubMedGoogle Scholar
- Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E: Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol. 1998, 179: 1565-1567. 10.1016/S0002-9378(98)70025-0.View ArticlePubMedGoogle Scholar
- Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, Meer van der FJ: Increased fetal loss in women with heritable thrombophilia. Lancet. 1996, 348: 913-916. 10.1016/S0140-6736(96)04125-6.View ArticlePubMedGoogle Scholar
- Brenner B, Kupferminc MJ: Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2003, 17: 427-439. 10.1016/S1521-6934(03)00006-3.View ArticlePubMedGoogle Scholar
- Zlotogora J, Leventhal A, Amitai Y: The impact of congenital malformations and Mendelian diseases on infant mortality in Israel. IMAJ. 2003, 5: 416-418.PubMedGoogle Scholar
- Vardi-Saliternik R, Friedlander Y, Cohen T: Consanguinity in a population sample of Israeli Muslim Arabs, Christian Arabs and Druze. Ann Hum Biol. 2002, 29: 422-431. 10.1080/03014460110100928.View ArticlePubMedGoogle Scholar
- Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA: Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Reprod Biol. 1998, 80: 49-54. 10.1016/S0301-2115(98)00083-9.View ArticleGoogle Scholar
- Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M: Thromboprophylaxis with low molecular weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost. 1997, 77: 39-41.PubMedGoogle Scholar
- Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Marès P: Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004, 103: 3695-3699. 10.1182/blood-2003-12-4250.View ArticlePubMedGoogle Scholar
- Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997, 314: 253-257.PubMed CentralView ArticlePubMedGoogle Scholar
- Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996, 174: 1584-1589. 10.1016/S0002-9378(96)70610-5.View ArticlePubMedGoogle Scholar
- Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002, 100: 408-413. 10.1016/S0029-7844(02)02165-8.View ArticlePubMedGoogle Scholar
- Kalk JJ, Huisjes AJ, de Groot CJ, van Beek E, van Pampus MG, Spaanderman ME, van Eyck J, Oei SG, Bezemer PD, de Vries JI: Recurrence rate of pre-eclampsia in women with thrombophilia influenced by low-molecular-weight heparin treatment?. Neth J Med. 2004, 62: 83-87.PubMedGoogle Scholar
- Pabinger I, Vormittag R: Thrombophilia and pregnancy outcomes. J Thromb Haemost. 2005, 3: 1603-1610. 10.1111/j.1538-7836.2005.01417.x.View ArticlePubMedGoogle Scholar
- Blumenfeld Z, Brenner B: Thrombophilia-associated pregnancy wastage. Fertil Steril. 1999, 72: 765-774. 10.1016/S0015-0282(99)00360-X.View ArticlePubMedGoogle Scholar
- Coulam CB, Wallis D, Weinstein J, Dasgupta DS, Jeyendran RS: Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. Am J Reprod Immunol. 2008, 60: 426-431. 10.1111/j.1600-0897.2008.00640.x.View ArticlePubMedGoogle Scholar
- Nelen WL: Hyperhomocysteinaemia and human reproduction. Clin Chem Lab Med. 2001, 39: 758-763. 10.1515/CCLM.2001.126.View ArticlePubMedGoogle Scholar
- Dossenbach-Glaninger A, van Trotsenburg M, Krugluger W, Dossenbach MR, Oberkanins C, Huber J, Hopmeier P: Elevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Haemost. 2004, 91: 694-699.PubMedGoogle Scholar
- Kemkes-Matthes B, Nees M, Kuhnel G, Matzdorff A, Matthes KJ: Protein Z influences the prothrombotic phenotype in factor V Leiden patients. Thromb Res. 2002, 106: 183-185. 10.1016/S0049-3848(02)00181-0.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.